Pediatric generalized anxiety disorder: Epidemiology, diagnosis, and management

Pediatric Drugs

Volumn 11, Issue 3, 2009, Pages 171-183

  Keeton, Courtney Pierce ^a,b   Kolos, Amie C ^a   Walkup, John T ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS CHILDREN S CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUSPIRONE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADOLESCENT; ANAMNESIS; ANOREXIA; ANXIETY DISORDER; APATHY; ASTHENIA; BEHAVIOR DISORDER; BIPOLAR MANIA; BIPOLAR SWITCHING; BLEEDING; CAPILLARY RESISTANCE; CHILD; CHILD PSYCHIATRY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC INTERVIEW SCHEDULE; DISEASE COURSE; DROWSINESS; DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EPISTAXIS; EVENING DOSAGE; FAMILY HISTORY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; GROWTH RETARDATION; HEADACHE; HEALTH CARE QUALITY; HUMAN; LABORATORY TEST; LEG CRAMP; LOW DRUG DOSE; MAJOR DEPRESSION; MANIA; MORNING DOSAGE; PAIN; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOEDUCATION; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RESTLESSNESS; REVIEW; SCHOOL CHILD; SEMI STRUCTURED INTERVIEW; SEPARATION ANXIETY; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; STOMACH PAIN; TREATMENT DURATION; XEROSTOMIA;

ADOLESCENT; ANXIETY DISORDERS; CHILD; COGNITIVE THERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS;

EID: 66049102935     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200911030-00003     Document Type: Review

References (110)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
2. Silverman WK, Eisen AR. Age differences in the reliability ofparent and child reports of child anxious symptomatology using a structured interview. J Am Acad Child Adolesc Psychiatry 1992; 31 (1): 117-24
3. Beidel DC. Social phobia and overanxious disorder in school-age children. J Am Acad Child Adolesc Psychiatry 1991; 30 (4): 545-52
4. Kendall PC, Warman MJ. Anxiety disorders in youth: diagnostic consistency across DSM-III-R and DSM-IV. J Anxiety Disord 1996; 10 (6): 452-63
5. Costello EJ, Egger HL, Angold A. The developmental epidemiology of anxiety disorders: phenomenology, prevalence, and comorbidity. Child Adolesc Psychiatr Clin N Am 2005; 14 (4): 631-48
6. Breslau J, Aguilar-Gaxiola S, Kendler KS, et al. Specifying race-ethnic differences in risk for psychiatric disorder in a USA national sample. Psychol Med 2006; 36 (1): 57-68
7. Lewinsohn PM, Gotlib IH, Lewinsohn M, et al. Gender differences in anxiety disorders and anxiety symptoms in adolescents. J Abnorm Psychol 1998; 107 (1): 109-17
8. Masi G, Millepiedi S, Mucci M, et al. Generalized anxiety disorder in referred children and adolescents. J Am Acad Child Adolesc Psychiatry 2004; 43 (6): 752-60
9. Pine DS. Research review: a neuroscience framework for pediatric anxiety disorders. J Child Psychol Psychiatry 2007; 48 (7): 631-48
10. Vasey MW, Dadds MR. An introduction to the developmental psychopathology of anxiety. In: Vasey MW, Dadds MR, editors. The developmental psychopathology of anxiety. New York: Oxford University Press, 2001: 3-26
11. Ialongo N, Edelsohn G, Werthamer-Larsson L, et al. The significance of self-reported anxious symptoms in first-grade children. J Abnorm Child Psychol 1994; 22 (4): 441-55
12. Chavira DA, Stein MB, Bailey K, et al. Child anxiety in primary care: prevalent but untreated. Depress Anxiety 2004; 20 (4): 155-64
13. Masi G, Mucci M, Favilla L, et al. Symptomatology and comorbidity of generalized anxiety disorder in children and adolescents. Compr Psychiatry 1999; 40 (3): 210-5
14. Verduin TL, Kendall PC. Differential occurrence of comorbidity within childhood anxiety disorders. J Clin Child Adolesc Psychol 2003; 32 (2): 290-5
15. Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003; 42 (4): 415-23
16. The Research Units on Pediatric Psychopharmacology Anxiety Study Group (RUPP). Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 2001; 344 (17): 1279-85
17. Blair K, Shaywitz J, Smith BW, et al. Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry 2008; 165 (9): 1193-202
18. Pine DS, Cohen P, Gurley D, et al. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry 1998; 55 (1): 56-64
19. Gould RA, Otto MW, Pollack MH, et al. Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analysis. Behav Ther 1997; 28 (2): 285-305
20. Research Units on Pediatric Psychopharmacology Anxiety Study Group. The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry 2002; 41 (9): 1061-9
21. Moffitt TE, Caspi A, Harrington H, et al. Generalized anxiety disorder and depression: childhood risk factors in a birth cohort followed to age 32. Psychol Med 2007; 37 (3): 441-52
22. Last CG, Perrin S, Hersen M, et al. A prospective study of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1996; 35 (11): 1502-10
23. Kaplow JB, Curran PJ, Angold A, et al. The prospective relation between dimensions of anxiety and the initiation of adolescent alcohol use. J Clin Child Psychol 2001; 30 (3): 316-26
24. Sartor CE, Lynskey MT, Heath AC, etal. The role of childhood risk factors in initiation of alcohol use and progression to alcohol dependence. Addiction 2007; 102 (2): 216-25
25. Connolly SD, Bernstein GA. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 2007; 46 (2): 267-83
26. Grills AE, Ollendick TH. Multiple informant agreement and the anxiety disorders interview schedule for parents and children. J Am Acad Child Adolesc Psychiatry 2003; 42 (1): 30-40
27. Schniering CA, Hudson JL, Rapee RM. Issues in the diagnosis and assessment of anxiety disorders in children and adolescents. Clin Psychol Rev 2000; 20 (4): 453-78
28. Safford SM, Kendall PC, Flannery-Schroeder E, et al. A longitudinal look at parent-child diagnostic agreement in youth treated for anxiety disorders. J Clin Child Adolesc Psychol 2005; 34 (4): 747-57
29. Wood JJ, McLeod BD, Sigman M, et al. Parenting and childhood anxiety: theory, empirical findings, and future directions. J Child Psychol Psychiatry 2003; 44 (1): 134-51
30. Puliafico AC, Kendall PC. Threat-related attentional bias in anxious youth: a review. Clin Child Fam Psychol Rev 2006; 9 (3): 162-80
31. Weems CF, Zakem AH, Costa NM, et al. Physiological response and childhood anxiety: association with symptoms of anxiety disorders and cognitive bias. J Clin Child Adolesc Psychol 2005; 34 (4): 712-23
32. Ginsburg GS, Riddle MA, Davies M. Somatic symptoms in children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 2006; 45 (10): 1179-87
33. Hofflich SA, Hughes AA, Kendall PC. Somatic complaints and childhood anxiety disorders. Int J Clin Health Psychol 2006; 6 (2): 229-42
34. Kaufman J, Birmaher B, Brent DA, et al. The Schedule for Affective Disorders and Schizophrenia for School-Age Children: Present and Lifetime Version (version 1.0). Pittsburgh (PA): University of Pittsburgh School of Medicine, 1996
35. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36 (7): 980-8
36. March JS, Parker JDA, Sullivan K, et al. The MultidimensionalAnxiety Scale for Children (MASC): factor structure, reliability, and validity. J Am Acad Child Adolesc Psychiatry 1997; 36 (4): 554-65
37. Birmaher B, Brent DA, Chiappetta L, et al. Psychometric properties of the Screen for Child Anxiety Related Emotional Disorders (SCARED): a replication study. J Am Acad Child Adolesc Psychiatry 1999; 38 (10): 1230-6
38. Muris P, Merckelbach H, Schmidt H, et al. The revised version of the Screen for Child Anxiety Related Emotional Disorders (SCARED-R): factor structure in normal children. Pers Individ Dif 1999; 26 (1): 99-112
39. Muris P, Dreessen L, Bogels S, et al. A questionnaire for screening a broad range of DSM-defined anxiety disorder symptoms in clinically referred children and adolescents. J Child Psychol Psychiatry 2004; 45 (4): 813-20
40. Spence SH. Structure of anxiety symptoms among children: a confirmatory factor-analytic study. J Abnorm Psychol 1997; 106 (2): 280-97
41. Chorpita BF, Yim L, Moffitt C, et al. Assessment of symptoms of DSM-IV anxiety and depression in children: a revised child anxiety and depression scale. Behav Res Ther 2000; 38 (8): 835-55
42. Baldwin JS, Dadds MR. Reliability and validity of parent and child versions of the multidimensional anxiety scale for children in community samples. J Am Acad Child Adolesc Psychiatry 2007; 46 (2): 252-60
43. Rynn MA, Barber JP, Khalid-Khan S, et al. The psychometric properties of the MASC in a pediatric psychiatric sample. J Anxiety Disord 2006; 20 (2): 139-57
44. Dierker LC, Albano AM, Clarke GN, et al. Screening for anxiety and depression in early adolescence. J Am Acad Child Adolesc Psychiatry 2001; 40 (8): 929-36
45. Wood JJ, Piacentini JC, Bergman RL, et al. Concurrent validity of the anxiety disorders section of the Anxiety Disorders Interview Schedule for DSM-IV: child and parent versions. J Clin Child Adolesc Psychol 2002; 31 (3): 335-42
46. Birmaher B, Khetarpal S,Brent D,et al. The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry 1997; 36 (4): 545-53
47. Muris P, Merckelbach H, Mayer B, et al. The Screen for Child Anxiety Related Emotional Disorders (SCARED) and traditional childhood anxiety measures. J Behav Ther Exp Psychiatry 1998; 29 (4): 327-39
48. Wren FJ, Berg EA, Heiden LA, et al. Childhood anxiety in a diverse primary care population: parent-child reports, ethnicity and SCARED factor structure. J Am Acad Child Adolesc Psychiatry 2007; 46: 332-40
49. Spence SH, Barrett PM, Turner CM. Psychometric properties of the Spence Children's Anxiety Scale with young adolescents. J Anxiety Disord 2003; 17 (6): 605-25
50. Nauta MH, Scholing A, Rapee RM, et al. A parent-report measure of children's anxiety: psychometric properties and comparison with child-report in a clinic and normal sample. Behav Res Ther 2004; 42 (7): 813-39
51. Spence SH. A measure of anxiety symptoms among children. Behav Res Ther 1998; 36 (5): 545-66
52. Chorpita BF, Moffitt CE, Gray J. Psychometric properties of the Revised Child Anxiety and Depression Scale in a clinical sample. Behav Res Ther 2005; 43 (3): 309-22
53. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008; 359 (26): 2753-66
54. Langley AK, Bergman RL, McCracken J, et al. Impairment in childhood anxiety disorders: preliminary examination of the child anxiety impact scale-parent version. J Child Adolesc Psychopharmacol 2004; 14 (1): 105-14
55. Muris P, Merckelbach H, Ollendick TH, et al. What is the Revised Fear Survey Schedule for Children measuring? Behav Res Ther 2002 11; 40 (11): 1317-26
56. Velting ON, Setzer NJ, Albano AM. Update on and advances in assessment and cognitive-behavioral treatment of anxiety disorders in children and adolescents. Prof Psychol Res Pr 2004; 35 (1): 42-54
57. Myers K, Winters NC. Ten-year review of rating scales: II. Scales for internalizing disorders. J Am Acad Child Adolesc Psychiatry 2002; 41 (6): 634-59
58. Ginsburg GS, Siqueland L, Masia-Warner C, et al. Anxiety disorders in children: Family matters. Cogn Behav Pract 2004; 11 (1): 28-43
59. Brown AM, Deacon BJ, Abramowitz JS, et al. Parents' perceptions of pharmacological and cognitive-behavioral treatments for childhood anxiety disorders. Behav Res Ther 2007; 45 (4): 819-28
60. Merikangas KR. Vulnerability factors for anxiety disorders in children and adolescents. Child Adolesc Psychiatr Clin N Am 2005; 14 (4): 649-79
61. Keller MB, Lavori PW, Wunder J,et al. Chronic course of anxiety disorders in children and adolescents. J Am Acad Child Adolesc Psychiatry 1992; 31 (4): 595-9
62. Kendall PC. Treating anxiety disorders in children: results of a randomized clinical trial. J Consult Clin Psychol 1994; 62 (1): 100-10
63. Kendall PC, Flannery-Schroeder E, Panichelli-Mindel SM, et al. Therapy for youths with anxiety disorders: a second randomized clincal trial. J Consult Clin Psychol 1997; 65 (3): 366-80
64. King NJ, Heyne D, Ollendick TH. Cognitive-behavioral treatments for anxiety and phobic disorders in children and adolescents: a review. Behav Disord 2005; 30 (3): 241-57
65. Compton SN, McKnight CD, March JS. Combining medication and psychosocial treatments: an evidence-based medicine approach. New York: Guilford Press, 2004
66. Gould RA, Buckminster S, Pollack MH, et al. Cognitive-behavioral and pharmacological treatment for social phobia: a meta-analysis. Clin Psychol Sci Pract 1997; 4 (4): 291-306
67. Durham RC, Chambers JA, MacDonald RR, et al. Does cognitive behavioural therapy influence the long-term outcome of generalized anxiety disorder? An 8-14 year follow-up of two clinical trials. Psychol Med 2003; 33 (3): 499-509
68. Ishikawa S, Okajima I, Matsuoka H, et al. Cognitive behavioural therapy for anxiety disorders inchildren and adolescents: ameta-analysis. Child Adolesc Ment Health 2007; 12 (4): 164-72
69. Kendall PC. Cognitive-behavioral therapy for anxious children: therapist manual. 2nd ed. Ardmore (PA): Workbook Publishing, 2000
70. Gosch EA, Flannery-Schroeder E, Mauro CF, et al. Principles of cognitive-behavioral therapy for anxiety disorders in children. J Cogn Psychother 2006; 20 (3): 247-62
71. Kendall PC, Treadwell KRH. Cognitive-behavioral treatment for childhood anxiety disorders. Washington, DC: American Psychological Association, 1996
72. Bouchard S, Mendlowitz SL, Coles ME, et al. Considerations in the use of exposure with children. Cogn Behav Pract 2004; 11 (1): 56-65
73. Kendall PC, Braswell L. Medical applications of cognitive-behavioral interventions with children. J Dev Behav Pediatr 1986; 7 (4): 257-64
74. Grover RL, Hughes AA, Bergman RL, et al. Treatment modifications based on childhood anxiety diagnosis: demonstrating the flexibility in manualized treatment. J Cogn Psychother 2006; 20 (3): 275-86
75. Birmaher B, Waterman GS, Ryan N, et al. Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1994; 33 (7): 993-9
76. Compton SN, Grant PJ, Chrisman AK, et al. Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry 2001; 40 (5): 564-71
77. Dummit III ES, Klein RG, Tancer NK, et al. Fluoxetine treatment of children with selective mutism: an open trial. J Am Acad Child Adolesc Psychiatry 1996; 35 (5): 615-21
78. Reinblatt SP, Riddle MA. The pharmacological management of childhood anxiety disorders: a review. Psychopharmacology (Berl) 2007; 191 (1): 67-86
79. Rynn MA, SiquelandL,Rickels K.Placebo-controlled trialofsertralineinthe treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158 (12): 2008-14
80. Rynn MA, Riddle MA, Yeung PP, et al. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry 2007; 164 (2): 290-300
81. Simeon JG, Ferguson HB, Knott V, et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry 1992; 31 (1): 29-33
82. Bridge J, Iyengar S, Salary C, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297 (15): 1683-96
83. Clark DB, Birmaher B, Axelson D, et al. Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. J Am Acad Child Adolesc Psychiatry 2005; 44 (12): 1263-70
84. Emslie GJ, Rush AJ, Weinberg WA, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54: 1031-7
85. Brady K, Pearstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000; 283: 1837-44
86. March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial [published erratum appears in JAMA 2000; 283: 1293] JAMA 1998; 280: 1752-6
87. Bernstein GA, Borchardt CM, Perwien AR, et al. Imipramine plus cognitive-behavioral therapy in the treatment of school refusal. J Am Acad Child Adolesc Psychiatry 2000; 39 (3): 276-83
88. Gittelman-Klein R, Klein DF. Controlled imipramine treatment of school phobia. Arch Gen Psychiatry 1971; 25: 204-7
89. Klein RG, Koplewicz HS, Kanner A. Imipramine treatment of children with separation anxiety disorder. J Am Acad Child Adolesc Psychiatry 1992; 31 (1): 21-8
90. Bernstein GA, Borchardt CM, Perwien AR. Anxiety disorders in children and adolescents: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 1996; 35 (9): 1110-9
91. Bernstein GA, Hektner JM, Borchardt CM, etal. Treatment of school refusal: one-year follow-up. J Am Acad Child Adolesc Psychiatry 2001; 40 (2): 206-13
92. Roberts R, Rodriguez W, Murphy D, et al. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 2003; 290 (7): 905-11
93. March JS, Entusah AR, Rynn M, et al. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry 2007; 62 (10): 1149-54
94. Wagner KD, Berard R, Stein MB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004; 61 (11): 1153-62
95. Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003; 157 (1): 17-25
96. Libby AM, Brent DA, Morrato EH, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. Am J Psychiatry 2007; 164 (6): 884-91
97. Nemeroff CB, Kalali A, Keller MB, et al. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 2007; 64 (4): 466-72
98. Rosack J. New data show declines in antidepressant prescribing. Psychiatr News 2005; 40 (17): 1-39
99. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63 (3): 332-9
100. USFDA. Revisions tomedication guide [online]. Available from URL: http://www.fda.gov/cder/drug/antidepressants/antidepressants-MG-2007.pdf. [Accessed 2007 Jul 15]
101. Walkup J, Labellarte M. Current thinking: complications of SSRI treatment. J Child Adolesc Psychopharmacol 2001; 11 (1): 1-4
102. Rynn MA, Brawman-Mintzer O. Generalized anxiety disorder: acute and chronic treatment. CNS Spectr 2004; 9 (10): 716-23
103. Weintrob N, Cohen D, Klipper-Aurbach Y, et al. Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 2002; 156 (7): 696-701
104. Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol 2006; 16 (1): 159-69
105. Martin A, Young C,Leckman JF, et al. Age effectson antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004; 158 (8): 773-80
106. Reinblatt SP, Riddle MA. Selective serotonin reuptake inhibitor-induced apathy: a pediatric case series. J Child Adolesc Psychopharmacol 2006; 16 (1): 227-33
107. Garland EJ, Baerg EA. A motivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents. J Child Adolesc Psychopharmacol 2001; 11 (2): 181-6
108. Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med 2006; 119 (9): 719-27
109. Lake MB, Birmaher B, Wassick S, et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol 2000; 10 (1): 35-48
110. Pine DS. Treating children and adolescents with selective serotonin reuptake inhibitors: how long is appropriate? J Child Adolesc Psychopharmacol 2002; 12 (3): 189-203